Your browser is no longer supported. Please, upgrade your browser.
TCDA Tricida, Inc. weekly Stock Chart
TCDA [NASD]
Tricida, Inc.
Index- P/E- EPS (ttm)-4.30 Insider Own2.20% Shs Outstand49.84M Perf Week-2.94%
Market Cap1.31B Forward P/E- EPS next Y-3.74 Insider Trans-3.90% Shs Float48.53M Perf Month1.50%
Income-213.00M PEG- EPS next Q-1.46 Inst Own99.70% Short Float10.19% Perf Quarter-7.00%
Sales- P/S- EPS this Y-53.40% Inst Trans0.17% Short Ratio12.43 Perf Half Y-28.69%
Book/sh3.98 P/B6.48 EPS next Y30.70% ROA-57.30% Target Price- Perf Year-22.16%
Cash/sh5.57 P/C4.62 EPS next 5Y- ROE-76.00% 52W Range18.02 - 44.30 Perf YTD-31.69%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-41.81% Beta-
Dividend %- Quick Ratio5.60 Sales past 5Y- Gross Margin- 52W Low43.02% ATR1.18
Employees141 Current Ratio5.60 Sales Q/Q- Oper. Margin- RSI (14)40.66 Volatility3.82% 4.79%
OptionableYes Debt/Eq0.30 EPS Q/Q-65.90% Profit Margin- Rel Volume0.95 Prev Close26.00
ShortableYes LT Debt/Eq0.30 EarningsMay 07 AMC Payout- Avg Volume397.84K Price25.78
Recom2.00 SMA20-3.39% SMA50-6.20% SMA200-19.48% Volume377,949 Change-0.83%
Jun-27-19Initiated Goldman Buy $48
May-24-19Initiated Needham Buy $50
Jul-23-18Initiated JP Morgan Neutral $34
Jul-23-18Initiated Goldman Neutral $32
Jun-15-20 12:24PM  
Jun-03-20 04:39PM  
Jun-02-20 10:00AM  
May-22-20 04:05PM  
May-20-20 12:32AM  
May-19-20 08:13AM  
May-08-20 03:01PM  
May-07-20 04:05PM  
Apr-30-20 10:00AM  
Apr-09-20 11:43AM  
Apr-07-20 08:03PM  
Mar-24-20 08:30AM  
Mar-13-20 01:56PM  
Mar-12-20 09:00AM  
Mar-09-20 08:30AM  
Feb-24-20 04:15PM  
Feb-19-20 10:00AM  
Jan-07-20 01:59PM  
Dec-24-19 11:55AM  
Dec-11-19 02:30PM  
Dec-03-19 08:00AM  
Nov-25-19 10:00AM  
10:00AM  
Nov-14-19 04:08PM  
04:03PM  
Nov-05-19 10:00AM  
Oct-25-19 10:12AM  
Oct-04-19 10:24AM  
Oct-02-19 08:30AM  
Sep-12-19 08:56AM  
Sep-04-19 08:30AM  
Aug-10-19 12:09AM  
Aug-08-19 04:05PM  
Aug-01-19 10:00AM  
Jun-27-19 07:33AM  
07:28AM  
Jun-25-19 09:01PM  
08:30AM  
Jun-18-19 11:10AM  
Jun-17-19 08:32AM  
Jun-05-19 10:00AM  
May-08-19 08:45PM  
04:05PM  
May-03-19 09:25AM  
Apr-30-19 10:13AM  
Apr-23-19 12:29PM  
Apr-08-19 05:03PM  
04:05PM  
Apr-04-19 09:57AM  
Apr-03-19 08:07PM  
09:16AM  
Apr-01-19 04:39PM  
04:36PM  
05:34AM  
Mar-28-19 04:37PM  
03:57PM  
11:33AM  
07:15AM  
07:07AM  
07:00AM  
06:00AM  
Mar-27-19 04:44PM  
Mar-11-19 08:30AM  
Mar-07-19 10:00AM  
Feb-27-19 10:00AM  
Jan-17-19 08:30AM  
Jan-02-19 02:00PM  
Dec-20-18 10:35PM  
Nov-08-18 04:05PM  
Nov-01-18 10:00AM  
Oct-04-18 04:26PM  
Aug-08-18 04:05PM  
03:00PM  
Aug-01-18 08:30AM  
Jul-31-18 05:43PM  
Jul-23-18 04:27PM  
Jul-18-18 08:01PM  
12:26PM  
Jul-02-18 04:05PM  
07:30AM  
Tricida, Inc., a pharmaceutical company, focuses on the development and commercialization of its drug candidate, TRC101, a non-absorbed, orally-administered polymer designed as a potential treatment for metabolic acidosis in patients with chronic kidney disease (CKD). The company has completed a Phase 3, double-blind, placebo-controlled trial of TRC101 in patients with CKD and metabolic acidosis. Tricida, Inc. was founded in 2013 and is headquartered in South San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
KLAERNER GERRITPresident and CEOJul 01Sale27.154,000108,600547,321Jul 02 04:57 PM
KLAERNER GERRITPresident and CEOJun 15Sale25.974,000103,86929,323Jun 16 08:14 PM
KLAERNER GERRITPresident and CEOJun 01Sale26.234,000104,920551,321Jun 03 04:39 PM
KLAERNER GERRITPresident and CEOMay 15Sale31.564,000126,22033,323May 19 07:07 PM
Parker Geoffrey M.Chief Fin. Officer and EVPMay 12Buy30.912,74284,76695,000May 12 08:45 PM
Parker Geoffrey M.Chief Fin. Officer and EVPMay 11Buy30.0232,258968,43792,258May 12 08:45 PM
Otto Dawn ParsellEVP, Clinical DevelopmentMay 08Option Exercise3.033,0009,0991,692May 12 08:38 PM
Otto Dawn ParsellEVP, Clinical DevelopmentMay 08Sale31.983,00095,940255May 12 08:38 PM
Otto Dawn ParsellEVP, Clinical DevelopmentMay 05Option Exercise1.941,2502,4211,053May 07 05:33 PM
Otto Dawn ParsellEVP, Clinical DevelopmentMay 05Sale30.141,25037,680255May 07 05:33 PM
KLAERNER GERRITPresident and CEOMay 01Sale27.984,000111,906555,321May 04 05:34 PM
Otto Dawn ParsellEVP, Clinical DevelopmentApr 29Option Exercise2.823,0008,4501,999Apr 30 04:33 PM
Otto Dawn ParsellEVP, Clinical DevelopmentApr 29Sale31.983,00095,940255Apr 30 04:33 PM
Otto Dawn ParsellEVP, Clinical DevelopmentApr 28Option Exercise1.681,2502,1001,505Apr 30 04:33 PM
Otto Dawn ParsellEVP, Clinical DevelopmentApr 28Sale29.981,25037,475255Apr 30 04:33 PM
KLAERNER GERRITPresident and CEOApr 15Sale27.474,000109,89137,323Apr 16 08:05 PM
KLAERNER GERRITPresident and CEOApr 06Sale24.224,00096,880559,321Apr 08 04:34 PM
KLAERNER GERRITPresident and CEOMar 16Sale23.914,00095,64041,323Mar 18 04:09 PM
Parker Geoffrey M.Chief Fin. Officer and EVPMar 10Buy29.465,000147,30055,000Mar 11 05:10 PM
HEJLEK EDWARD JEVP, General Counsel & Secy.Mar 02Option Exercise0.9610,0009,60028,953Mar 04 07:36 PM
Otto Dawn ParsellEVP, Clinical DevelopmentMar 02Option Exercise2.484,25010,5503,249Mar 04 07:38 PM
HEJLEK EDWARD JEVP, General Counsel & Secy.Mar 02Sale31.6610,000316,61619,153Mar 04 07:36 PM
Otto Dawn ParsellEVP, Clinical DevelopmentMar 02Sale31.844,250135,316255Mar 04 07:38 PM
KLAERNER GERRITPresident and CEOMar 02Sale31.534,000126,120563,321Mar 04 07:33 PM
KLAERNER GERRITPresident and CEOFeb 18Sale36.104,000144,40045,323Feb 20 04:42 PM
Stahl WilhelmChief Tech Officer & Sr. VPFeb 05Option Exercise1.6850084015,306Feb 06 05:07 PM
Stahl WilhelmChief Tech Officer & Sr. VPFeb 05Sale38.9150019,45514,806Feb 06 05:07 PM
HEJLEK EDWARD JSVP, General Counsel & Secy.Feb 03Option Exercise0.9610,0009,60027,022Feb 05 09:29 PM
Otto Dawn ParsellSr VP, Clinical DevelopmentFeb 03Option Exercise2.484,25010,5503,249Feb 05 09:31 PM
Otto Dawn ParsellSr VP, Clinical DevelopmentFeb 03Sale36.864,250156,668255Feb 05 09:31 PM
HEJLEK EDWARD JSVP, General Counsel & Secy.Feb 03Sale36.4210,000364,16919,153Feb 05 09:29 PM
KLAERNER GERRITPresident and CEOFeb 03Sale36.334,000145,330567,321Feb 05 09:27 PM
KLAERNER GERRITPresident and CEOJan 15Sale35.264,000141,04049,323Jan 16 06:06 PM
HEJLEK EDWARD JSVP, General Counsel & Secy.Jan 02Option Exercise0.9610,0009,60029,101Jan 06 04:33 PM
Otto Dawn ParsellSr VP, Clinical DevelopmentJan 02Option Exercise1.684,2507,1402,620Jan 06 04:35 PM
Otto Dawn ParsellSr VP, Clinical DevelopmentJan 02Sale37.044,250157,421255Jan 06 04:35 PM
HEJLEK EDWARD JSVP, General Counsel & Secy.Jan 02Sale37.0210,000370,15119,153Jan 06 04:33 PM
KLAERNER GERRITPresident and CEOJan 02Sale37.154,000148,607571,321Jan 03 04:38 PM
HEJLEK EDWARD JSVP, General Counsel & Secy.Dec 26Option Exercise0.964,2004,03219,082Dec 30 04:46 PM
Stahl WilhelmChief Tech Officer & Sr. VPDec 23Option Exercise1.663,0004,99217,756Dec 26 04:36 PM
Stahl WilhelmChief Tech Officer & Sr. VPDec 23Sale38.913,000116,73014,806Dec 26 04:36 PM
HEJLEK EDWARD JSVP, General Counsel & Secy.Dec 20Option Exercise0.9615,00014,40029,882Dec 23 05:26 PM
HEJLEK EDWARD JSVP, General Counsel & Secy.Dec 20Sale38.1715,000572,55014,882Dec 23 05:26 PM
KLAERNER GERRITPresident and CEODec 18Sale38.9131,7501,235,45753,323Dec 20 05:30 PM
Bonita David PDirectorDec 11Sale40.001,500,00060,000,0009,614,280Dec 12 05:23 PM
ORBIMED ADVISORS LLCDirectorDec 11Sale40.001,500,00060,000,0009,614,280Dec 12 05:20 PM
KLAERNER GERRITPresident and CEODec 11Sale43.507,572329,346575,321Dec 12 07:27 PM
COUFAL SANDRA IDirectorDec 10Sale43.171,62069,9354,860Dec 12 07:31 PM
COUFAL SANDRA IDirectorDec 10Sale43.2871330,859216,939Dec 12 07:31 PM
KLAERNER GERRITPresident and CEODec 10Sale43.283,948170,869582,893Dec 11 08:34 PM
KLAERNER GERRITPresident and CEODec 02Sale39.494,000157,960586,841Dec 03 04:27 PM
KLAERNER GERRITPresident and CEONov 29Sale39.802,00079,60085,073Dec 03 04:27 PM
KLAERNER GERRITPresident and CEONov 29Sale39.802,00079,600590,841Dec 03 04:27 PM
Otto Dawn ParsellSr VP, Clinical DevelopmentNov 26Option Exercise1.515,7468,6512,355Nov 27 04:34 PM
Otto Dawn ParsellSr VP, Clinical DevelopmentNov 26Sale39.605,746227,5490Nov 27 04:34 PM
Alpern Robert JDirectorNov 26Sale39.591,00039,590137,390Nov 27 04:26 PM
COUFAL SANDRA IDirectorNov 22Sale41.00180,8647,415,4322,773,350Nov 26 07:09 PM
Isern Brian M.possible member of 10% groupNov 22Sale41.00180,8647,415,4322,773,350Nov 26 05:50 PM
COUFAL SANDRA IDirectorNov 21Sale40.98190,6827,815,043777,411Nov 22 08:30 PM
Isern Brian M.possible member of 10% groupNov 21Sale40.98190,6827,815,043777,411Nov 22 05:48 PM
Stahl WilhelmChief Tech Officer & Sr. VPNov 20Option Exercise1.688141,36815,620Nov 21 07:13 PM
Stahl WilhelmChief Tech Officer & Sr. VPNov 20Sale40.8181433,21914,806Nov 21 07:13 PM
Alpern Robert JDirectorNov 20Sale40.652,43999,145138,390Nov 21 07:09 PM
COUFAL SANDRA IDirectorNov 20Sale39.99112,1054,483,1816,480Nov 22 08:30 PM
COUFAL SANDRA IDirectorNov 20Sale40.2171328,670217,652Nov 22 08:30 PM
Isern Brian M.possible member of 10% groupNov 20Sale39.99110,5854,422,016836,505Nov 22 05:48 PM
Parker Geoffrey M.Chief Fin. Officer and Sr. VPNov 19Buy34.7294532,81050,000Nov 19 04:51 PM
Parker Geoffrey M.Chief Fin. Officer and Sr. VPNov 18Buy34.2819,055653,20549,055Nov 19 04:51 PM
Stahl WilhelmChief Tech Officer & Sr. VPNov 12Option Exercise1.688361,40415,642Nov 14 06:52 PM
Alpern Robert JDirectorNov 12Sale39.921,15946,267140,829Nov 14 06:54 PM
Stahl WilhelmChief Tech Officer & Sr. VPNov 12Sale39.9783633,41514,806Nov 14 06:52 PM
Stahl WilhelmChief Tech Officer & Sr. VPNov 07Option Exercise1.682,9104,88917,716Nov 12 06:56 PM
Stahl WilhelmChief Tech Officer & Sr. VPNov 07Sale39.972,910116,31314,806Nov 12 06:56 PM
Alpern Robert JDirectorNov 07Sale39.933,953157,843141,988Nov 12 06:53 PM
COUFAL SANDRA IDirectorNov 07Sale40.021004,0028,000Nov 12 06:51 PM